Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap
Gene Therapy Launch Delayed Again
Executive Summary
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.
You may also be interested in...
Bluebird Bio Restructures Amid Financial Woes, But Will It Fly?
The firm is laying off a big piece of its workforce and deprioritizing some investments to free up capital for potential upcoming launches, but that could add commercial risks.
Bluebird CFO Leaves The Nest As Company Reveals Grim Cash Position
Its Q4 earnings report was not the first time that bluebird mentioned selling priority review vouchers it has not received yet, but the PRV revenue is needed to fund operations beyond 2022.
Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.